Skip to content

Study · Non-randomized trial · n = 14 · 2008

11 results

Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.

Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, Gerich J, Göke B, Schirra J

American journal of physiology. Endocrinology and metabolism30 Oct 2007Cited by 47 (Europe PMC)

PMID17971511 (opens in a new tab)DOI10.1152/ajpendo.00514.2007 (opens in a new tab)PepBankPUB-17971511
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialMechanism

    In healthy subjects, gastric retention differed between placebo and pramlintide at 60 minutes, but the sentence does not explicitly assign direction.

    In plain wordsIn healthy people, gastric retention differed between placebo and pramlintide at 60 minutes, without an explicit direction.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Direction not reportedGastric retention at 60 minutes
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At 60 min, greater proportions of the initial gastric contents remained in the stomach (PBO vs. PRAM).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  2. 02HumanNon-randomized trialMechanism

    In healthy subjects, gastric emptying slopes were parallel after 60 minutes until 240 minutes with pramlintide and placebo.

    In plain wordsIn healthy people, gastric emptying slopes were parallel with pramlintide and placebo after 60 minutes until 240 minutes.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeGastric emptying slopes
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Thereafter, GE slopes paralleled until 240 min.
    2 context sentences
    Summary · context
    At 60 min, greater proportions of the initial gastric contents remained in the stomach (PBO vs. PRAM).
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  3. 03HumanNon-randomized trialMechanism

    In healthy subjects, gastric half-retention time was longer with pramlintide than placebo.

    In plain wordsIn healthy people, half the meal stayed in the stomach longer with pramlintide than placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseGastric half-retention time
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Fifty percent retention times were lower when PBO was given (P < 0.001).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  4. 04HumanNon-randomized trialMechanism

    In healthy subjects, gastric emptying was greater late in the pramlintide experiment than with placebo.

    In plain wordsIn healthy people, late gastric emptying was greater with pramlintide than placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseLate gastric emptying
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    GE was greater from 240 min to the end of the PRAM experiments, so that only slightly greater proportions of the meal remained in the stomach at 330 min.
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  5. 05HumanNon-randomized trialMechanism

    In healthy subjects, only slightly more meal remained in the stomach at 330 minutes with pramlintide than placebo.

    In plain wordsIn healthy people, slightly more meal remained in the stomach at 330 minutes with pramlintide than placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseGastric retention at 330 minutes
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    GE was greater from 240 min to the end of the PRAM experiments, so that only slightly greater proportions of the meal remained in the stomach at 330 min.
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy subjects, pramlintide lowered postprandial glucose compared with placebo.

    In plain wordsIn healthy people, pramlintide lowered glucose after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Measurements

    Postprandial glucose
    7.5 mmol/l
    placebo
    Postprandial glucose
    6 mmol/l
    pramlintide

    Source sentences

    Summary
    Reductions of GE lowered pp glucose (7.5 +/- 0.3 vs. 6.0 +/- 0.2 mmol/l, P < 0.001), even though plasma insulin was lower with PRAM (164 +/- 13 vs. 138 +/- 13 pmol/ml, both P < 0.01).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  7. 07HumanNon-randomized trialMechanism

    In healthy subjects, pramlintide lowered plasma insulin compared with placebo.

    In plain wordsIn healthy people, pramlintide lowered blood insulin compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePlasma insulin
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Measurements

    Plasma insulin
    164 pmol/ml
    placebo
    Plasma insulin
    138 pmol/ml
    pramlintide

    Source sentences

    Summary
    Reductions of GE lowered pp glucose (7.5 +/- 0.3 vs. 6.0 +/- 0.2 mmol/l, P < 0.001), even though plasma insulin was lower with PRAM (164 +/- 13 vs. 138 +/- 13 pmol/ml, both P < 0.01).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  8. 08HumanNon-randomized trialMechanism

    In healthy subjects, pramlintide reduced total glucose appearance compared with placebo.

    In plain wordsIn healthy people, pramlintide reduced total glucose entering the blood compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseTotal glucose appearance
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Reduction in total glucose appearance (P < 0.001) was due to reduced meal-derived glucose appearance (10.2 +/- 0.5 vs. 7.0 +/- 0.4 micromol.kg(-1).min(-1), P < 0.001).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  9. 09HumanNon-randomized trialMechanism

    In healthy subjects, pramlintide reduced meal-derived glucose appearance compared with placebo.

    In plain wordsIn healthy people, pramlintide reduced meal-derived glucose entering the blood compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseMeal-derived glucose appearance
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Measurements

    Meal-derived glucose appearance
    10.2 micromol/kg/min
    placebo
    Meal-derived glucose appearance
    7 micromol/kg/min
    pramlintide

    Source sentences

    Summary
    Reduction in total glucose appearance (P < 0.001) was due to reduced meal-derived glucose appearance (10.2 +/- 0.5 vs. 7.0 +/- 0.4 micromol.kg(-1).min(-1), P < 0.001).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  10. 10HumanNon-randomized trialMechanism

    In healthy subjects, pramlintide increased endogenous glucose appearance compared with placebo.

    In plain wordsIn healthy people, pramlintide increased the body's glucose entering the blood compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseEndogenous glucose appearance
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Endogenous glucose appearance was greater with PRAM (P < 0.001).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.
  11. 11HumanNon-randomized trialMechanism

    In healthy subjects, pramlintide increased splanchnic glucose uptake compared with placebo.

    In plain wordsIn healthy people, pramlintide increased glucose uptake by abdominal organs compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseSplanchnic glucose uptake
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg · subcutaneousAs given in this study (human).

    Measurements

    Splanchnic glucose uptake
    26.5%
    placebo
    Splanchnic glucose uptake
    32.5%
    pramlintide

    Source sentences

    Summary
    Splanchnic glucose uptake was greater with PRAM (26.5 +/- 1.6 vs. 32.5 +/- 2.1%, P = 0.014).
    1 context sentence
    Summary · context
    Fourteen healthy subjects (8 men, 6 women; age 40 +/- 3 yr, body mass index 27.8 +/- 1.1 kg/m2) ate a mixed meal, and 30 microg of pramlintide (PRAM) or placebo (PBO) were injected subcutaneously.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.